{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T07:11:02Z","timestamp":1776496262681,"version":"3.51.2"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/00511"],"award-info":[{"award-number":["PI14\/00511"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.cca.2018.10.034","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T21:27:31Z","timestamp":1540848451000},"page":"50-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Measurement of ceftolozane and tazobactam concentrations in plasma by UHPLC-MS\/MS. Clinical application in the management of difficult-to-treat osteoarticular infections"],"prefix":"10.1016","volume":"488","author":[{"given":"Ra\u00fal","family":"Rigo-Bonnin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Gomez-Junyent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Garc\u00eda-Tejada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Benavent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Soldevila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fe","family":"Tubau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Murillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2018.10.034_bb0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11908-018-0629-6","article-title":"Multidrug-resistant pseudomonas infections: hard to treat, but hope on the horizon?","volume":"20","author":"Nguyen","year":"2018","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.cca.2018.10.034_bb0010","doi-asserted-by":"crossref","first-page":"212527","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.cca.2018.10.034_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.cca.2018.10.034_bb0020","first-page":"3357","article-title":"Osteoarticular infection caused by MDR Pseudomonas aeruginosa: the benefits of combination therapy with colistin plus \u03b2-lactams","volume":"70","author":"Ribera","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cca.2018.10.034_bb0025","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2014.10.024","article-title":"ESCMID guideline for the diagnosis and treatment of biofilm infections 2014","volume":"21","author":"Hoiby","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.cca.2018.10.034_bb0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/38.1.5","article-title":"Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations","volume":"38","author":"Mouton","year":"1996","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cca.2018.10.034_bb0035","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1345\/aph.1M717","article-title":"High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients","volume":"44","author":"Moriyama","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.cca.2018.10.034_bb0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s15010-018-1116-6","article-title":"Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use","volume":"46","author":"Ribera","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.cca.2018.10.034_bb0045","first-page":"3178","article-title":"Therapeutic drug monitoring of the \u03b2-lactam antibiotics: what is the evidence and which patients should we be using it for?","volume":"70","author":"Huttner","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.cca.2018.10.034_bb0050","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4155\/bio-2017-0257","article-title":"Validated HPLC-UV detection method for the simultaneous determination of ceftolozane and tazobactam in human plasma","volume":"10","author":"Garin","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.cca.2018.10.034_bb0055","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/chromsci\/bmw047","article-title":"Development of an HPLC method for the determination of ceftolozane\/tazobactam in biological and aqueous matrixes","volume":"54","author":"Sutherland","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.cca.2018.10.034_bb0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/AAC.00727-15","article-title":"Pharmacodynamics of ceftolozane plus tazobactam studied in an in vitro pharmacokinetic model of infection","volume":"60","author":"MacGowan","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cca.2018.10.034_bb0065","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/cpdd.429","article-title":"Safety, tolerability, and pharmacokinetics of 3 g of ceftolozane\/tazobactam in healthy adults: a randomized, placebo-controlled, multiple-dose study","volume":"7","author":"Yu","year":"2018","journal-title":"Clin. Pharm. Drug Dev."},{"key":"10.1016\/j.cca.2018.10.034_bb0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/jcph.395","article-title":"Population pharmacokinetics of ceftolozane\/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections","volume":"22","author":"Chandorkar","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.cca.2018.10.034_bb0075","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1128\/AAC.06349-11","article-title":"Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses","volume":"56","author":"Miller","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.cca.2018.10.034_bb0080","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2017.03.009","article-title":"Development and validation of a measurement procedure based on ultra-high performance liquid chromatography-tandem mass spectrometry for simultaneous measurement of \u03b2-lactam antibiotic concentration in human plasma","volume":"468","author":"Rigo-Bonnin","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2018.10.034_bb0085","series-title":"Guideline on Bioanalytical Method Validation","author":"European Medicines Agency","year":"2011"},{"key":"10.1016\/j.cca.2018.10.034_bb0090","series-title":"Evaluation of Precision of Quantitative Analysis Measurement Procedures; Approved Guideline","author":"Clinical and Laboratory Standards Institute","year":"2014"},{"key":"10.1016\/j.cca.2018.10.034_bb0095","series-title":"Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline (EP06-A)","author":"Clinical and Laboratory Standard Institute","year":"2003"},{"key":"10.1016\/j.cca.2018.10.034_bb0100","series-title":"Liquid Chromatography-Mass Spectrometry Methods; Approved Guideline (CLSI C62-A)","author":"Clinical and Laboratory Standard Institute","year":"2014"},{"key":"10.1016\/j.cca.2018.10.034_bb0105","series-title":"International Federation of Clinical Chemistry and Laboratory Medicine, Mass Spectrometry in the Clinical Laboratory: General Principles and Guidance; Approved Guideline (CLSI C50-A)","author":"Clinical and Laboratory Standards Institute","year":"2007"},{"key":"10.1016\/j.cca.2018.10.034_bb0110","series-title":"Expression of Measurement Uncertainty in Laboratory Medicine; Approved Guideline (CLSI EP29-A)","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.cca.2018.10.034_bb0115","unstructured":"European Federation of National Associations of Measurement, Testing and Analytical Laboratories, Measurement uncertainty revisited: alternative approaches to uncertainty evaluation, EUROLAB Technical Report No. 1\/2007, http:\/\/www.eurolab.org\/documents\/1-2007.pdf, 2007 (accessed 30 May 2018)."},{"key":"10.1016\/j.cca.2018.10.034_bb0120","unstructured":"European Federation of National Associations of Measurement, Testing and Analytical Laboratories, Guide to the evaluation of measurement uncertainty for quantitative test results, EUROLAB Technical Report No. 1\/2006, http:\/\/www.eurolab.org\/documents\/EL_11_01_06_387%20Technical%20report%20-%20Guide_Measurement_uncertainty.pdf, 2006 (accessed 30 May 2018)."},{"key":"10.1016\/j.cca.2018.10.034_bb0125","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1007\/s11095-007-9291-7","article-title":"Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays","volume":"24","author":"Viswanathan","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.cca.2018.10.034_bb0130","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1515\/cclm-2013-0721","article-title":"Clinical sample stability and measurement uncertainty","volume":"52","author":"Fuentes-Arderiu","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2018.10.034_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00216-007-1693-1","article-title":"Treatment of uncorrected measurement bias in uncertainty estimation for chemical measurements","volume":"390","author":"Magnusson","year":"2008","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.cca.2018.10.034_bb0140","first-page":"1","article-title":"Guidelines of the German Medical Association on quality assurance in medical laboratory testing, Doc03 (20150408)","volume":"6","author":"Bundes\u00e4rztekammer","year":"2015","journal-title":"GMS Z Forder Qualitatssich Med. Lab."},{"key":"10.1016\/j.cca.2018.10.034_bb0145","series-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standard Institute","year":"2018"},{"key":"10.1016\/j.cca.2018.10.034_bb0150","first-page":"137","article-title":"Properties and units in the clinical laboratory sciences, Part XXIII, the NPU terminology, principles, and implementation: a user's guide (IUPAC Technical Report)","volume":"84","author":"Magdal","year":"2012","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.cca.2018.10.034_bb0155","series-title":"Antimicrobial Wild Type Distributions of Microorganisms","author":"European Committee on Antimicrobial Susceptibility Testing, European Society of Clinical Microbiology and Infectious Diseases","year":"2018"},{"key":"10.1016\/j.cca.2018.10.034_bb0160","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1515\/cclm-2015-0325","article-title":"Effects of biobanking conditions on six antibiotic substances in human serum assessed by a novel evaluation protocol","volume":"54","author":"Zander","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2018.10.034_bb0165","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1515\/cclm-2014-0833","article-title":"Exploration of the preanalytical stability of \u03b2-lactam antibiotics in plasma and blood\u2014Implications for therapeutic drug monitoring and pharmacokinetic studies","volume":"53","author":"Carlier","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2018.10.034_bb0170","series-title":"Medical Laboratories, Requirements for Quality and Competence, ISO 15189","author":"International Organization for Standardization","year":"2012"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898118305606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898118305606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T09:05:49Z","timestamp":1544519149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898118305606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":34,"alternative-id":["S0009898118305606"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2018.10.034","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Measurement of ceftolozane and tazobactam concentrations in plasma by UHPLC-MS\/MS. Clinical application in the management of difficult-to-treat osteoarticular infections","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2018.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}